Warning: Undefined variable $insensitive in
/home/u792129758/domains/sciencefather.com/public_html/academicawards/wp-content/plugins/internal-link-building-plugin/internal_link_building.php on line
201
Warning: Undefined variable $insensitive in
/home/u792129758/domains/sciencefather.com/public_html/academicawards/wp-content/plugins/internal-link-building-plugin/internal_link_building.php on line
202
Dr Jianglan Long,Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University,China
Dr. Jianglan Long is a dedicated Researcher Intern at Beijing Institute of Clinical Pharmacy, affiliated with Beijing Friendship Hospital and Capital Medical University. Specializing in intelligent molecular diagnostics and drug intervention mechanisms for pre-diabetes and type 2 diabetes, Dr. Long has published several impactful papers. Notable works include studies in International Journal of Biological Macromolecules (2024) on innovative diabetes treatments, and contributions to Diabetes Obesity & Metabolism (2024) on predictive biomarker profiling. Dr. Long is a pioneer in developing integrated diagnostic tools and advancing diabetes treatment in China. 🌟🔬📚
Publication profile
Scopus
Academic and Professional Background
Dr. Jianglan Long is a prominent researcher based at the Beijing Institute of Clinical Pharmacy, affiliated with Beijing Friendship Hospital, Capital Medical University. His primary focus lies in the exploration of intelligent molecular diagnosis and drug intervention mechanisms for prediabetes and type 2 diabetes. Dr. Jianglan Long has made significant contributions to this field, evidenced by his publications in reputable journals such as the International Journal of Biological Macromolecules (2024), Diabetes Obesity & Metabolism (2024), Clinical and Translational Medicine (2021), BMC Endocrine Disorders (2020), and Rapid Communications in Mass Spectrometry (2020), where he served as the first author.
Research focus
Category: Research Focus on Intelligent Molecular Diagnosis and Drug Intervention for Diabetes
Jianglan Long’s research centers on advancing the field of intelligent molecular diagnostics and drug interventions for pre-diabetes and type 2 diabetes. Her work includes pioneering biomarker profiling for early disease detection and the enhancement of metformin therapy with innovative treatments, like low molecular weight polysaccharides from Astragalus membranaceus. With twelve published journals and ongoing research, her contributions are crucial for improving diabetes management and treatment outcomes in China and potentially worldwide. 📊🔬💊🌍
Publication top notes
Structural characterization of Astragalus polysaccharide-D1 and its improvement of low-dose metformin effect by enriching Staphylococcus lentus
Uncovering the key pharmacodynamic material basis and possible molecular mechanism of Xiaoke formulation improve insulin resistant through a comprehensive investigation
Rapid multichannel fluorescent probe assay for CYP450 inhibition screening and drug interaction monitoring
Novel weight loss diet attenuates dietary-induced obesity in mice and might correlate with altered gut microbiota and metabolite profiles
Polystyrene microplastic exposure induces insulin resistance in mice via dysbacteriosis and pro-inflammation
Evaluation of interaction of chlorogenic acid and cefotaxime sodium based on sequential analysis
Network pharmacology-based dissection of the underlying mechanisms of dyspnoea induced by zedoary turmeric oil
Metabolomics based plasma biomarkers for diagnosis of oral squamous cell carcinoma and oral erosive lichen planus